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Abstract: Cancer gene therapy emerged as a promising treatment modality 3 decades ago. However, the failure of the first gene therapy
trials in cancer treatment has decreased its popularity. Likewise, immunotherapy has followed a similar course. While it was a popular
and promising treatment with IL-2 and interferon and cancer vaccines in the 1980s, it later lost its popularity. Immunotherapy became
one of the main options for cancer treatment with the successful use of immune checkpoint inhibitors in clinics approximately 10 years
ago. The success of immunotherapy has increased even more with the introduction of cancer gene therapy methods in this area. With
the identification of the oncolytic herpes simplex virus and Chimeric antigen receptor (CAR) T-cells, immune gene therapy has become
an essential modality in cancer treatments such as surgery, radiotherapy, chemotherapy, and targeted therapies.
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1. Introduction
Recently, the use of new immunotherapeutic agents
such as immune checkpoint inhibitors (ICIs),
Chimeric antigen receptor (CAR) T-cells, and
oncolytic viruses have increased median survival times
in cancer. Unexpected long-term remissions with
the use of several monoclonal antibodies targeting
immune checkpoints such as cytotoxic T-lymphocyteassociated antigen 4 (CTLA-4), or programed death 1
(PD1)/programed death-ligand 1 (PD-L1) have raised
the hope for a cure in advanced solid tumors [1].
Combining immunotherapy agents with or without
cytotoxic treatments has resulted in further synergistic
activity [2].
Cancer gene therapy has often been studied since
the late 1990s as a promising agent in cancer treatment;
however, only limited success has been achieved in
humans. Talimogene laherparepvec (T-VEC), the first
approved gene therapy product in cancer, has fueled
gene therapy studies aiming to induce tumor-specific
immunity. T-VEC is an oncolytic herpes simplex
virus modified to proliferate only in tumor cells and
carry the granulocyte-macrophage colony-stimulating
factor (GM-CSF) gene [3].The GM-CSF produced in
the tumor microenvironment induces tumor-specific
immunity through the presentation of released tumor
antigens by dendritic cells attracted via GM-CSF.

With the emerging role of immunotherapy in
cancer, the conventional gene therapy methods that have
been studied for about 30 years have started to be used
to target the immune system. Like ICIs, immune targeted
gene therapy approaches may yield long-term remissions
in advanced cancer patients. Additionally, the combination
of cytotoxic gene therapy treatments, such as suicide
gene therapy and oncolytic vectors, aiming at tumor cell
killing and immune-stimulation, might further increase
therapeutic efficacy. In this paper, we will mainly focus on
immune system targeted gene therapy.
2. Gene delivery systems
Cancer gene therapy can be defined as the introduction of
a therapeutic gene (transgene) into a tumor cell utilizing
a delivery vehicle, called a vector. There are 2 major
categories of vehicles for transporting the transgenes: viral
and nonviral vectors. Nonviral vectors include the physical
and chemical transfer methods of genes and bacterial and
cellular vehicles. Nonviral transfer methods are usually
safe and easy to use, but the transfection efficiency is
usually lower than the viral vectors [4].
Electroporation, aiming at disrupting cell membranes
using high voltage electrical pulses to facilitate the entry
of DNA molecules into the cell, is a popular physical
method of nonviral transport of transgenes being tested in
clinical trials [5]. Likewise, nanoparticles carrying genetic
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material are also widely studied to deliver genes into the
cells. Some bacteria, like E. coli and S. typhimurium, are
used to transfer suicide genes to tumor tissues and induce
host immune responses against tumors [6].Genetically
engineered bacteria are usually safe and cheaper compared
to viral vectors [6].However, the use of bacteria as gene
therapy vehicles is limited in immune-targeted gene
therapies.
Viral vectors are widely used gene delivery vehicles
in cancer treatment. The clinical trials that have been
conducted so far have mainly utilized adenoviral vectors,
adeno-associated viral vectors, herpes simplex viruses
(HSVs), alfa viruses, retroviral vectors, and lentiviral
vectors. Widely used viral vectors and their features
are outlined in Table 1. Because of genomic integration,
retroviral vectors and lentiviral vectors are the least
preferable vectors in cancer gene therapy trials. However,
lentiviral vectors are widely used for ex vivo modification
of immune cells, such as DCs and T-lymphocytes [7].
Adenoviral vectors and adeno-associated vectors are
commonly used to introduce therapeutic genes to tumor
cells.
Adenoviruses are the most preferred viral vectors
because they can express therapeutic genes episomally
and have no risk of integration into the genome. Firstgeneration adenoviral vectors have been used as carriers
for the treatment of monogenic diseases by removing the
E1 gene region of the vector [8]. However, first-generation
adenoviral vectors are highly immunogenic, and a high
prevalence of neutralizing antibodies in humans limits
their clinical use. Besides, first-generation adenoviral
vectors may also produce replication-competent forms
during and after the production process [9]. To relieve
the disadvantages mentioned above, second-generation
adenoviral vectors were obtained by removing the E2 and
E4 gene regions of the virus [10]. Adenoviral vectors can
transduce almost all cells and are safe because they do
not integrate into the genome. Likewise, transient gene

expression in cells seen in adenoviral vector transductions
is not an issue for cancer treatment. First and secondgeneration adenoviral vectors have a cargo capacity of
fewer than 8 kb [10]. In order to overcome this limited cargo
capacity, third-generation vectors have been obtained by
further modifying the adenovirus. In this generation, all
adenovirus genes have been removed except the package
signals, and the cargo capacity was increased to 30 kb
and called gutless vectors [11]. The vast cargo capacity of
third-generation adenoviral vectors makes them attractive
vehicles for cancer gene therapy. The gutless vectors
have been tested in various in vitro cancer models [12].
Nevertheless, they need further improvements to increase
their therapeutic potential.
Adeno-associated viruses are small nonenveloped
DNA viruses from the Parvovirus group that cause latent
infection in cells. They can infect both dividing and
nondividing cells and integrate the genes they carry into the
host genome. Because genome integration is site-specific
in chromosomes, the risk of insertional mutagenesis is
not as high as in retroviruses [13]. Since the transient
gene expression is usually sufficient for cancer treatment,
adeno-associated vectors have not been studied much in
cancer treatment. In addition, their limited capacity of 4
kb cargo or less is another obstacle for the transfer of big
gene constructs [14].
Alphaviruses from the Togaviridae family are used in
cancer gene therapy to stimulate cytotoxic T-cell response
[15]. The Semliki forest virus and Sindbis virus in this
group are essential vectors that have the potential for
cancer gene therapy [16].
HSVs have a high cargo capacity because of their
complex genomes. As the genome size is as large as the
app. 150kb, up 30 kb, genetic material can easily be loaded
[17]. Not being integrated into the host genome is another
advantage in terms of cancer gene therapy. Removing the
immediate early genes of the virus reduces the replication
capabilities to prevent the possible toxicities of the virus

Table 1. Viral vectors commonly used in gene therapy studies.
Viral vector

Packaging
capacity (kb)

Features

Adenovirus

≤ 7.5

Transient expression in most of the cells, immunogenic.

Adeno-associated virus (AAV)

≤4

Long-term expression in dividing and non-dividing cells.

Herpes Simplex virus

≥ 30

Long-term expression in most of the cells; low toxicity.

Alphaviruses

≤ 7.5

Transient gene expression in most of the cells including neurons and glial
cells; low immunogenicity.

Retrovirus

8

Long-term expression in dividing cells; genome integration.

Lentivirus

8

Long-term expression in both dividing and non-dividing cells; genome
integration.
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[17]. Modifications such as the deletion of the immediate
early gene ICP47, which will enable it to reproduce only
in cancer cells selectively make this vector a preferable
oncolytic viral agent [18]. T-VEC, as mentioned before,
acts as both an oncolytic vector and an immunestimulating agent with its GM-CSF cargo [19].
Retroviral vectors are the second most studied vector
group in cancer treatment. They are small RNA viruses
and integrate into the host genome following cell entry.
It is possible to load genetic material up to 10 kb by
removing the capsid, reverse transcriptase, and sheath
genes required for the replication of the virus [20]. As they
are stably integrated into the host genome, they provide
very long-term gene expression and have the potential for
insertional mutagenesis. Despite their handicaps, such as
low transduction efficiency and the inability to transduce
nondividing cells, they are frequently used in cancer gene
therapy [21].
Lentiviruses are a select group of retroviruses and are
attractive because of their ability to transduce nondividing
cells. They also provide long-term gene expression and
low potential for inflammation. However, they can
integrate into the host genome and carry the potential for
insertional mutagenesis. The lentiviral vectors are mainly
used to modify the T-cells [22].
3. Immunological targets in cancer gene therapy
Cancer gene therapy mainly aims to transfer therapeutic
genes, gene segments, or oligonucleotides either with in
vivo or ex vivo approaches to the target cells. The immune
system is the most crucial target for the treatment of
cancer. The main immunological targets for cancer gene
therapy outlined in Table 2 are cytokine/chemokine genes,
tumor-associated antigens, fusion proteins, including
tumor antigens, genetically modified tumor cells, or
immune cells.
The target cells are sometimes the tumor cells
themselves in the immune gene therapy of cancer. In this
method, gene therapy vehicles are directed against tumor
cells to destroy or make them sensitive to the host immune
system. Gene therapy can also target the host immune
cells to make them specifically active against tumor cells.
Immune cells, such as cytotoxic T-cells and dendritic
cells, can also be modified exvivo utilizing gene therapy
methods before administering to patients.
3.1. Tumor cells as targets for immune gene therapy
Gene therapy methods aiming at direct tumor cell killing,
such as oncolytic vectors and suicide genes, can also
induce tumor-specific immunity. Previously, we and other
researchers have shown that tumor antigens shed from
dying tumor cells may induce antitumor immunity that
further improves therapeutic results [23,24]. Viruses that
have cytotoxic effects against human cells were suggested

Table 2. The main immunological targets in the treatment of
cancer gene therapy.
Tumor cells
Immunuostimulatory cytokines (GM-CSF, IL-12, CD40L, IL-12)
T-cells
NK cells
Suicide genes (Cytosine deaminase, Thymidine kinase)
Oncolytic vectors

as a treatment modality decades ago [25]. However,
natural cytotoxic viruses (oncolytic viruses) usually failed
in clinical trials. HSVs, adenoviruses, parvoviruses, and
retroviruses have been modified so far to increase their
therapeutic capacity and have been tested in clinical trials
[26].
In a previous experimental tumor model, we showed
that replication-competent adenoviral vectors carrying
L-plastin (Lp)-driven E1a adenoviral vectors yielded
significant antitumor specific immune cell killing when
compared to the control ones [24,27]. Likewise, oncolytic
viruses may also induce an antitumor immune response
via increasing the tumor antigen shedding.
Immune gene therapy methods have been tested in
various cancer cells and experimental tumor models
with success. We previously designed various adenoviral
vectors carrying either cytosine deaminase (CD) gene or
immunostimulatory genes. Recently, we tested whether the
combination of CD/5-fluorocytosine (5-FC) gene therapy,
with the capability to kill tumor cells by converting 5-FC
into 5-fluorouracil (5-FU) in the tumor tissue, along with
an immunostimulatory GM-CSF gene, would further
increase therapeutic efficacy and augment the magnitude
of the antitumor immune response induced by the adjuvant
effect of dying tumor cells (Figure). We constructed an
adenoviral vector carrying both CD and GM-CSF genes
driven by the cytomegalovirus (CMV) promoter to achieve
this goal. The in vivo efficacy of the new adenoviral vector
design of the bicistronic transcription unit of CD and
GM-CSF and exogenous 5-FC tested in a syngeneic colon
cancer model was successful [28]. Suicide gene therapy
and GM-CSF induced immunity have been found to be 5
times more effective than either CD or GM-CSF alone in
treatments along with the prolongation of survival times
in mice. The above-mentioned adenoviral vector construct
will soon be tested in a first-in-human clinical trial.
Combining
cytotoxic
treatments
with
immunostimulatory genes may increase therapeutic
efficiency. The addition of IL-2 gene therapy to suicide gene
therapies such as thymidine kinase (TK) has been shown to
increase an antitumor response [29]. The immune system
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Figure. The adenoviral construct carrying cytosine deaminase and GM-CSF genes under the control of a CMV promoter produces
CD and GM-CSF in tumor cells. The 5-FU produced in the tumor cell with the help of CD from 5-florocytosine, an anti-mycotic drug,
kills the tumor cell and cause tumor antigen shedding. At the same time, the GM-CSF produced by the vector in the tumor cell attracts
dendritic cells nearby. The immature DCs uptake tumor antigens and present to T-cells in lymph nodes. The armed T-cells then enter the
systemic circulation and fight against tumor cells wherever they meet. ( : Naïve T-cell, : Armed tumor-specific T- cell, : Immature
dendritic cell, : Mature dendritic cell, : Tumor cell, Adenoviral vector carrying cytosine deaminase (yellow) and GM-CSF (blue)
genes.)

plays a crucial role in the development of cancer. The tumor
microenvironment (TME) provides an immunosuppressive
milieu [30], in which the tumor cells usually evade the
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immune system. Cytokines such as IL-10, VEGF, and IDO
secreted by tumor cells suppress the cytotoxic T-cells [31].
Cells like MDSC, Tregs, and M2 type macrophages in the
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TME also suppress cytotoxic T lymphocytes. Likewise,
the low pH established by the lactate from the tumor cells
may further increase the immunosuppressive properties
of the microenvironment [32]. Therefore, modulation of
the tumor microenvironment by immunomodulatory
cytokines would be beneficial.
3.2. Genetically modified tumor cell vaccines
Gene therapy tools have long been used to modify
immune cells such as dendritic cells, cytotoxic T-cells, and
autologous or allogeneic tumor cells to induce antitumor
immunity. The GM-CSF gene is one of the prevalent
immune cytokine genes that transduces tumor cells or
dendritic cells [33]. In animal models, CT26 colon cancer
cells transduced with an adenoviral vector carrying
GM-CSF have induced strong antitumor immunity
against tumor cells and prevented tumor regrowth [34].
This strategy has been tested in various tumor models
successfully [35].
Clinical trials utilizing GM-CSF transduced autologous
or allogeneic cancer cell vaccines have not yielded the
same success rates as preclinical models. Though Tani
et al. reported 2 long-term survivors out of 4 vaccinated
patients with advanced renal cell carcinoma [36], no
consistent results have been reported with the GM-CSF
transduced autologous or allogeneic tumor cell vaccines
[37]. While no objective tumor responses were seen with
those vaccines, a slight increase in overall survival was
noticed.
The whole of tumor cells or tumor antigens, either
isolated from tumor lysates or synthetic ones, have been
used in vaccination trials. Although some promising
results reported in earlier trials utilized the vaccine as
an adjuvant treatment, those strategies usually yielded a
minimal success rate in advanced diseases [38]. Leukemia
cells cannot be recognized by immune cells. Manipulation
of those cells through gene therapy methods could increase
their antigenicity. One such possibility is to express CD40
ligand (CD40L) on the leukemic cells to make them capable
of antigen-presenting cells. The binding of CD40 expressing
immune cells like T-cells and nonimmune cells induces
CD95 mediated apoptosis of the leukemic cells [39]. In a
phase I study of modified autologous chronic lymphocytic
leukemia cells transduced with a replication-defective
adenoviral vector carrying CD40L (ISF35), transduced
leukemic cells made nontransduced leukemic cells present
antigens and induce death-receptor induced apoptosis.
They yielded clinical responses [40,41]. Later, tumor cells
modified with viral vectors carrying immunostimulatory
cytokine genes specifically were studied in clinical trials.
In this method, the modified tumor cells behave as cellular
vaccines via increasing tumor antigenicity and inducing
an immune response. Comparative analysis of a modified
vaccinia virus strain Ankara (MVA) encoding CD40L or

TRICOM-infected chronic lymphocytic leukemia (CLL)
cells showed an increased immunogenicity of those
infected cells [42]. Previously, the combined expression
of CD40L and IL-2, or OX40L by CLL cells transduced
with adenoviral vectors, has shown antileukemic immune
response [43]. Likewise, malignant B-cells from CLL
patients behave as antigen-presenting cells when infected
with the vectors carrying B7.1, ICAM-1, and LFA-3
costimulatory molecules [44]. A therapeutic melanoma
vaccine (AGI-101H) transduced with a fusion protein
consisting of soluble IL-6 receptor and IL-6 linked by a
flexible peptide chain was used in the adjuvant setting in
melanoma patients (44). In 2 single-arm phase II trials,
AGI-101H yielded a significant prolongation in DFS and
OS of stage IIB-IV resected melanoma patients compared
to historical controls [45]. Accordingly, in an advanced
melanoma cohort of 77 patients, the same vaccine yielded
an approximate 50% disease control rate with a median OS
of 17.3 months [46].
3.3. Immune cytokines as immune gene therapy tools
Cytokine and chemokine genes are widely studied in cancer
gene therapy. GM-CSF, interferon-gamma, interferonalpha, IL-2, IL-4, IL-24, and IL-12 are the best-known
examples of cytokines used in gene therapy studies [47].
The systemic use of cytokines, such as interferon-alpha
and IL-2, has caused significant toxicity in clinics, and
they are no longer in use [48,49]. However, the production
of those cytokines in the tumor microenvironment would
decrease the toxicity. The combination of cytokine genes
is also found to be effective in tumor models. Choi et al.
showed that the coexpression of IL-12 and GM-CSF in
the same oncolytic adenoviral vector could significantly
increase antitumor immunity and could be used as a
potential treatment agent in cancer [50].
Hwang et al. tested the coadministration of an
adenovirus-mediated IL-12 gene transfer and a cytosine
deaminase-based suicide vector followed by 5-FC
treatment [51]. The coadministration of both vectors
has yielded significantly higher tumor growth inhibition
and prolonged median survival time in RENCA tumorbearing mice.
4-1BB (CD137), an activation-induced costimulatory
molecule expressed on activated T-cells, is an essential
immune checkpoint regulator. The targeting of 4-1BB or
its ligand (4-1BBL), a member of the tumor necrosis factor
superfamily, may have the potential to induce antitumor
immune T-cell responses. A replication-deficient
adenoviral vector construct carrying 4-1BBL caused
significant tumor growth inhibition in cholangiocarcinoma
bearing mice [52]. Likewise, the coadministration of 2
different adenoviral vector constructs carrying either IL-12
or 4-1BBL yielded a significant antitumor T-cell response
and prolonged the survival time in a mouse model bearing
colon cancer (MCA26 cells) [53].
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Chemokines recruiting the immune effector cells
to the tumor microenvironment have also been used as
immunostimulatory targets in gene therapy. Lapteva et al.
tested the delivery of RANTES (CCL-5) via an adenoviral
vector. The intratumoral injection of Ad-RANTESE1a
resulted in significant tumor reduction by increasing the
infiltration of macrophages, CTLs, and dendritic cells in
the tumor microenvironment [54].
Tumor-associated antigens have long been tested as
peptide vaccines for the treatment of cancer. However, the
efficacy of those vaccines has been highly limited clinically.
Likewise, gene therapy vectors carrying tumor-associated
antigens have been tested with limited success, even in
tumor models [55,56]. However, combining immune
cytokine genes or checkpoint regulator genes with TAA
would increase the immune response. We previously
designed an adenoviral vector carrying a fusion gene
encoding the CD40L and MUC1 antigens. The fusion
protein yielded a significant antitumor immune response
in preclinical models [57,58]. We then combined this
vector vaccination with a prodrug/enzyme system. The
combination therapy further increased the efficacy [57].
The combination of cytokine genes and TAA has also
been tested in clinical trials [59]. An attenuated vaccinia
vector carrying IL2 and MUC1 was reported to be effective
in patients with advanced prostatic cancer [60]. Von
Mehren et al. tested a vector vaccine of canarypox virus
encoding B7.1 and carcinoembryonic antigen (CEA) in
patients with epithelial tumors expressing CEA in a phase
I trial [61]. Thirty-nine patients with CEA-expressing
tumors were immunized with the vector intradermally
every other week for 8 weeks. Eight out of 30 patients
completing 8 vaccination cycles had a stable disease status.
Although hundreds of different DNA vaccines have been
tested so far, no DNA vaccine is available on the market
yet.
Although oncolytic viruses have long been studied as
a cytotoxic treatment modality for cancer gene therapy,
they have resulted in only limited success in clinical
trials. Attempts to engineer those viruses to modulate
the immune system have produced better response
rates than in previous trials. HSV has been modified
to selectively proliferate in tumor cells only by deleting
TK, ribonucleotide reductase, or ICP34.5 genes alone or
in combination [62]. However, the addition of a copy of
the GM-CSF gene to the HSV vector further significantly
increased therapeutic efficacy [63,64]. Also, the addition
of the IL-12 gene to an oncolytic HER2-targeted HSV
showed improved efficacy for metastatic tumors [65].
CTLA4 and PD1 are the best-known inhibitor
molecules that appear on activated T-cells. Upon binding
of theB7.1 or PD-L1 molecules expressed on either tumor
cells or macrophages in the TME to the CTLA-4 or PD1
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receptors on activated T-cells, the T-cell responses are
inhibited and regressed [66]. The anti-CTL4, anti-PD1,
or anti-PD-L1 antibodies, called immune checkpoint
inhibitors (ICI), bind either receptor or ligands to augment
the previously acquired T-cell responses against tumor
cells. More than 10 monoclonal antibodies have already
been approved for the treatment of various solid tumors
like melanoma, lung cancer, and kidney cancer, and they
are already on the market [67].
The manipulation of immune checkpoint ligands
or receptors with gene therapy methods is also being
developed. One strategy is to introduce immune
checkpoint inhibitor genes to the viral vectors. Reul et
al. constructed an AAV vector carrying the antihuman
PD1 gene [68]. The AAV-anti-PD1 vector has successfully
produced monoclonal antibodies in tumor cells, both in
vitro and in vivo. Likewise, Wu et al. placed the scFv of
anti-PDL1 gene into a vesicular stomatitis virus (VSV),
which preferentially replicates in tumor cells [69]. The VSV
carrying scFv-PDL1 has shown potentially therapeutic
effects in a lung cancer mouse model with PD-L1/LLC
cells. This strategy can be easily used with other checkpoint
inhibitor molecules. Furthermore, the combination of ICIs
with immune gene therapy tools might further increase
therapeutic efficacy.
3.4. Genetically modified T-lymphocytes
T-cells are the primary effector cells fighting against
tumor cells. Tumor-infiltrating lymphocytes (TILs)
have long been suggested as a major effector population
against tumor cells. However, some reports regarding the
unfavorable prognostic role of the T-cell infiltrated tumor
tissues have raised doubts about the use of those cells in
patients [70]. Further characterization of the TILs revealed
that the Treg subpopulation of T-cells in those patients
resulted in an unfavorable prognosis [71]. Patients with
CD8 infiltrated cells usually had a favorable prognosis
[72]. The isolation of CD8+TILs from fresh tumor tissues
and infusion to the patient following the expansion of the
cells, so-called the adoptive transfer of T-cells, has emerged
as a promising immunotherapy modality. Rosenberg et al.
showed that the administration of TILs prepared from
fresh surgical specimens from melanoma patients in
conjunction with IL-2 and lymphodepletion yielded a 29%
5-year remission rate [73]. Adoptive transfer of TILs is
found to be effective in heavily-treated patients, even with
prior immunotherapies [74,75]. The number of T-cells, the
proportion of CD8+ cells, and the more differentiated form
of those CD8+ cells might affect therapeutic yields [76].
However, in a small, randomized study with 36 patients,
the enrichment of CD8+ TILs did not increase the response
rates compared to the unselected ones [77].
Although the adoptive transfer of TILs has resulted in
promising results in melanoma, the low yield of cells isolated
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from fresh tumor samples and their exhausted nature
make using those cells in other solid tumors a challenge.
To augment the amplitude of T-cells’ activity, they are
engineered to express tumor-specific T-cell receptors [78].
Clay et al. showed that the efficient transfer of the tumorassociated antigen-MART-1 reactive T-cell receptor to
human lymphocytes exerted significant antitumor activity
in vitro on MART-1 expressing melanoma cells [79]. Later,
this strategy was translated into a clinical trial in melanoma
patients by Morgan et al. [80]. Although a modest clinical
activity has been achieved in that first-in-human trial, the
durable objective responses in 2 patients were to herald
the success of current immunotherapies. In another firstin-human trial of the T-cell receptor-targeted against
E6 antigen of human papillomavirus in patients with
advanced cervical cancer, sustainable objective responses
were reported [81].
Due to the limited success of TILs in clinical trials, new
strategies are being developed that can ensure that T-cells
bind more tightly to tumor antigens. The most popular of
these are CAR T-cells that are already approved for some
indications in a clinical setting. The T-cell receptor (TCR)
loosely binds to the target antigen, and the tumor specifically
needs to be recognized by the antigen-presenting cells
before they can react. Since antibody-antigen binding is
more specific than TCR-antigen binding, and there is no
need for prior presentation: the TCR has been replaced by
the antigen-binding site of an antibody to develop potent
T-cells. A chimeric antigen receptor (CAR) was obtained
by using the antigen-binding region of a tumor-specific
antibody fused with costimulatory molecules involved in
signal transduction[82].The resultant chimeric antigen
receptor gene is introduced into the T-cell through a viral
vector to obtain more potent cytotoxic T-cells expressing
a large number of TAA specific receptors[82]. These cells
are then amplified in the laboratory and administered to
patients. In the first-generation CAR T-cells, the CD3ζ
chain, which plays a role in signal transduction and T-cell
activation, was added next to the scFv molecule that binds
to the antigen [83]. The antitumor effect of first-generation
CAR T-cells was limited, and the cells underwent apoptosis
after a certain period [84]. Costimulatory genes such as
CD28, CD134, and 4-1BB have been added to the receptor
in second and third-generation CAR T-cells [82]. Thus,
the antitumoral activities of the cells increased through
their ability to proliferate and secrete cytokines. Currently,
CAR T-cells targeting the CD19 antigens of malignant
lymphocytes have been approved for cancer treatment
and have started to be used successfully in hematological
malignancies, especially lymphoma and leukemia [85,86].
Although CAR T-cell therapy has limited use in solid
tumors due to the shortage of unique tumor specific
antigens, promising results have been reported in several

recent in vivo studies [87,88]. Xia et al. have successfully
used EGFR CAR T with potent and specific antitumor
activity against a triple-negative breast cancer model [89].
Likewise, CEA targeted CAR T-cells are also being tested
for tumors expressing CEA [90].
3.5. Genetically modified dendritic cells
Dendritic cells have long been used as central effector cells
for cancer vaccines. The most critical antigen-presenting
cells of the body are DCs. The antigen-presenting DCs
could be produced through the stimulation of peripheral
blood monocytes or CD34+ cells by GM-CSF and IL-4
within 3–6 days [91]. In order to further activate and
to increase the maturation of the DCs against specific
antigens, DCs are exposed to specific tumor antigens with
either synthetic antigenic peptides or irradiated tumor cells
for a few days. The tumor antigens-exposed DCs become
fully activated and ready to present the tumor antigens to
the immune cells. DCs have been safely tested in numerous
clinical trials with some limited local inflammatory
reactions and flu-like symptoms [92
–94]. However,
the efficacy of those trials was modest. Specifically, the
administration of DCs following surgery or cytotoxic
treatments such as chemotherapy and radiotherapy is the
most widely implemented strategy used to augment an
immune response while the tumor burden is at the lowest
level. Accordingly, cytotoxic therapy and DCs vaccines
have yielded synergistic activities [94].
Dendritic cells, exvivo transduced with either
immunostimulatory genes or tumor antigens and
synthetic peptides, have been administered to induce an
antitumor immune response. The dendritic cells activated
exvivo migrate to the lymph nodes when injected
subcutaneously and present tumor antigens to CD8+
cytotoxic T-cells and induce an immune response. Viral
vectors carrying tumor-associated antigens have been
used so far to activate DCs. We designed an adenoviral
vector carrying a fusion protein of CD40L and MUC1
tumor antigen [95]. We transduced the dendritic cells with
the vector carrying the CD40L-MUC1 fusion gene and
tested this in a syngeneic mouse model of breast cancer
intratumorally. The intratumoral injection of the dendritic
cells loaded with the vaccine vector induced a potent antitumor CD84+ T-cell response and yielded a significant
objective response. Furthermore, we also even achieved
an increased immune response and tumor response,
combined with the DC vaccination with suicide gene
therapy of a CD/5-FC system compared to vaccination
alone [95]. Adenoviral vectors, retroviral vectors, lentiviral
vectors, and adenoassociated viral vectors have also been
used to transduce DCs invitro [96]. A DC-based vaccine,
based on the exvivo activation of blood mononuclear cells
by a fusion protein consisting of GM-CSF and prostatic
acid phosphatase (Provenge, Dendreon, USA), has been
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approved by the FDA for metastatic prostatic carcinoma
[97]. Provenge has significantly extended the overall
survival time for castration-resistant metastatic prostate
carcinoma patients by 4 months [98]. In the case of
Sipuleucel-T, as well as in most of the clinical trials with
other DC-based vaccines, autologous monocyte-derived
DCs (moDCs) are used. However, moDCs are not efficient
enough for the recapitulation of the natural diversity of
DCs. They usually mimic inflammatory DCs. Therefore,
moDCs do not seem to be ideal candidates for cancer
vaccination.
The main problem with the exvivo activation of DCs
is the selection of the useful cell subset of DCs. Therefore,
strategies aiming at the invivo induction of DCs via
powerful antigenic constructs seem much better than the
ex vivo loading of DCs. The type and delivery methods of
antigens used and the protocols might affect the activity of
DC-based vaccines [99].
4. Conclusion
Immunotherapy, which started with IL-2 and interferonalpha in the late 1980s, later increased with the use of

ICIs and has become one of the main elements of cancer
treatment today. Immunotherapies have provided more
extended survival periods for up to more than 5 years
in many metastatic tumors such as melanoma and
lung cancers. A combination of immunotherapies with
conventional therapies such as cytotoxic chemotherapy
and radiotherapy further improved treatment outcomes.
Serious side effects seen in current immunotherapeutic
drugs have fueled further research efforts. The application
of gene therapy methods to this field has improved the side
effect profile of immunotherapy to more acceptable levels
and increased treatment efficiency. Suicide gene therapies,
which have cytotoxic effects on tumor cells, along
with oncolytic treatments achieved with immune gene
treatments, are therefore important in further increasing
the success rate of cancer treatments already attained so far
with ICIs and targeted therapies.
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